Physician profile
Bruce A Johnson
NPI 1912043621
$14,695.87
in general payments reported to CMS, 2019-2025
36 companies · $2,101 in 2025
The $2,101 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,773 · 2020: $1,977 · 2021: $1,290 · 2022: $1,811 · 2023: $2,269 · 2024: $2,475 · 2025: $2,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,765 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,765.30 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,907.52 | 2019-2025 | Evenity, Enbrel, Krystexxa |
| Abbvie INC. | $2,111.17 | 2019-2025 | |
| Ucb, INC. | $1,464.93 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $923.19 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $862.55 | 2019-2025 | |
| Glaxosmithkline, LLC. | $823.32 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $718.55 | 2019-2025 | Taltz |
| Janssen Biotech, INC. | $599.86 | 2019-2025 | Tremfya, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $533.92 | 2019-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $494.20 | 2020-2025 | Ofev, Cyltezo |
| Horizon Therapeutics Plc | $401.57 | 2019-2023 | Krystexxa |
| Genzyme Corporation | $393.00 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $311.87 | 2022-2025 | Evusheld, Bevespi Aerosphere |
| Janssen Scientific Affairs, LLC | $290.23 | 2023-2025 | Tremfya |
| Fresenius Kabi USA, LLC | $246.77 | 2023-2025 | Idacio, Tyenne |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $240.82 | 2022-2024 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $184.82 | 2023-2025 | Strensiq |
| Radius Health, INC. | $178.27 | 2020-2025 | Tymlos |
| Genentech USA, INC. | $150.27 | 2019-2025 | Actemra, Gazyva |
| Janssen Pharmaceuticals, INC | $118.10 | 2023-2025 | Opsumit, Uptravi |
| Actelion Pharmaceuticals US, INC. | $93.84 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $78.94 | 2022-2023 | Acthar |
| Hikma Pharmaceuticals USA | $67.17 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $63.23 | 2024 | Arcalyst |
| Sandoz INC. | $58.19 | 2023-2025 | Hyrimoz |
| Kiniksa Pharmaceuticals, Ltd. | $51.84 | 2023 | Arcalyst |
| Organon LLC | $50.19 | 2024 | |
| Ani Pharmaceuticals, INC. | $49.52 | 2023-2024 | Purified Cortrophin Gel |
| Celgene Corporation | $46.34 | 2019 | |
| Bioventus LLC | $39.71 | 2019 | |
| Sobi, INC | $29.08 | 2025 | |
| Hospira, INC. | $27.48 | 2024 | |
| Pacira Therapeutics, INC. | $25.88 | 2019 | |
| Medexus Pharma, INC. | $25.03 | 2019-2020 | |
| Biocon Biologics INC | $19.33 | 2024 | Hulio |
| Depuy Synthes Sales INC. | $15.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.